Fairness opinions › Segments

Specialty Outpatient Facilities fairness opinions

7 public-company healthcare transactions in Specialty Outpatient Facilities, 2010-2025, each with the banker's fairness opinion from the SEC filing: the DCF discount rate and terminal assumptions, the selected companies and precedent transactions, and the deal terms.

Valuation benchmarks

EV / LTM EBITDA
8.7x
median · n=7
EV / LTM revenue
1.41x
median · n=7
DCF discount rate (midpoint)
12.5%
median · n=7

Specialty Outpatient Facilities transactions with a fairness opinion, 2010-2025. Multiples are enterprise value over the last-twelve-months figure disclosed in the filing; the discount rate is the midpoint of the range the banker used in its DCF.

Bankers most often engaged in Specialty Outpatient Facilities

Marshall & Stevens (1) · Lazard (1) · J.P. Morgan (1) · Evercore (1) · William Blair (1) · Lazard Middle Market (1) · Dresner Partners (1)

All Specialty Outpatient Facilities transactions

AnnouncedTargetAcquirer EVEV/EBITDAEV/RevDCF rateFairness opinion
2025-12-23 FONAR Damadian family Acquisition Group $69.3M4.3x0.65x14.5% Marshall & Stevens
2017-04-11 Alliance Healthcare Services Tahoe Investment Group Co. $683M5.7x1.33x9.0%–10.0% Lazard
2017-01-09 Surgical Care Affiliates Optum $3.3B16.4x2.75x6.5%–7.5% J.P. Morgan
2016-06-15 AmSurg Envision Healthcare Holdings $7.1B12.0x2.29x6.3%–7.2% Evercore
2011-01-21 NovaMed Surgery Partners $214M7.8x1.41x12.0%–16.0% William Blair
2010-05-06 HealthTronics Endo Health Solutions $315M8.7x1.48x11.5%–13.5% Lazard Middle Market
2010-04-14 Dialysis Corporation of America U.S. Renal Care $112M14.1x1.13x12.0%–16.0% Dresner Partners
3,000+ healthcare deal-level valuation multiples
The Valuation database includes financial details for more than 3,000 healthcare M&A transactions, private and public, with deal-level multiples, categorized by segment, type, and year.
See the Valuation database →